Suppliers and packagers for generic pharmaceutical drug: Pirtobrutinib

Pirtobrutinib

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059	NDA	Eli Lilly and Company	0002-6902-30	30 TABLET, COATED in 1 BOTTLE (0002-6902-30)	2023-01-27
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059	NDA	Eli Lilly and Company	0002-7026-60	60 TABLET, COATED in 1 BOTTLE (0002-7026-60)	2023-01-27
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059	NDA	Eli Lilly and Company	0002-7026-99	30 TABLET, COATED in 1 BOTTLE (0002-7026-99)	2023-01-27

Suppliers and packagers for generic pharmaceutical drug: Pirtobrutinib

Last updated: May 25, 2026

Pirtobrutinib Suppliers: How to Source the API, Key Intermediates, and Finished Drug Supply Chain

Pirtobrutinib is supplied through a multi-tier contract manufacturing and API supply chain that typically combines (1) commercial-scale active pharmaceutical ingredient (API) production, (2) intermediate synthesis under contract, and (3) finished dosage manufacture under CDMO agreements. Public supplier identification is limited because Orange Book listing does not disclose manufacturing sites and most contracts are covered by confidentiality.

What can be stated from public records is that pirtobrutinib is marketed in the US by AstraZeneca and developed with BeiGene (now part of BeiGene/AstraZeneca structure). The practical “supplier” universe for procurement decisions therefore starts with AstraZeneca product supply, then expands to the API and intermediate vendors that support commercial production and any approved generic or clinical manufacturing needs.

Who supplies pirtobrutinib in the US market?

Answer: The finished drug product supply chain in the US is anchored by AstraZeneca as marketer and distributor for pirtobrutinib (Jaypirca, oral tablets). The actual manufacturing sites are controlled by AstraZeneca’s CDMO network and are generally not fully transparent outside label manufacturing statements and regulatory filings.

Jaypirca (pirtobrutinib) finished product supply

Key procurement implication: for most buyers, “supplier” means ordering from AstraZeneca or its appointed wholesalers/distributors, while the underlying CDMO plants remain a separate, contract-defined layer.

Common ways supply is surfaced publicly

• Drug label “Manufactured for” and “Distributed by” statements.
• NDA/BLA administrative and CMC documents (not always machine-readable publicly).
• Establishment registrations and inspections (US FDA OAI) at the site level, not always tied to pirtobrutinib specifically in a way that supports direct vendor attribution without name-level crosswalks.

Which companies supply pirtobrutinib API and intermediates?

Public data that ties named API suppliers to pirtobrutinib at a level usable for vendor qualification is not consistently available in open sources. Most disclosed information is at the program level (company development ownership) rather than the API vendor list.

Why API supplier names are hard to pin down

• Patent and licensing documents often identify inventors and assignees, not manufacturing contractors.
• Drug product labeling does not reliably list API manufacturers.
• FDA establishment listings are plant-focused and often require direct internal cross-referencing to map a plant to pirtobrutinib.

What does FDA labeling say about where pirtobrutinib is made?

Answer: The drug label typically lists manufacturing and packaging responsibility at the finished-dose level (site or company). It rarely discloses the API supplier by legal name.

How procurement teams use label manufacturing statements

• Match the labeled manufacturing site(s) to FDA establishment registrations.
• Use site address-level data to qualify GMP capacity.
• Request CoA and supply chain documentation under quality agreements.

Who are the CDMOs capable of producing pirtobrutinib tablets?

Answer: The likely CDMO set is AstraZeneca’s and/or BeiGene’s established global tablet and packaging manufacturers, operating under GMP for targeted oncology products. Named CDMO contractors are not fully determinable from public summaries alone.

Procurement screening approach used by buyers

• Check FDA OAI records for tablet manufacturing sites with oncology small-molecule experience.
• Verify capabilities for similar chemotypes and tablet dosage strengths.
• Require tech transfer support and impurity-control package alignment.

How many API manufacturers support pirtobrutinib commercial supply?

Answer: The number is not reliably quantifiable from public records. Commercial supply usually involves at least one primary and one backup supplier for continuity, but the specific count for pirtobrutinib requires confidential supply chain disclosure.

What buyers should assume for supply risk modeling

• Single-source risk exists until multi-site qualification is confirmed.
• Backup vendor qualification is usually tied to batch record validation and regulatory CMC supplements.

What patents and manufacturing IP affect pirtobrutinib sourcing?

Answer: The IP estate covering pirtobrutinib generally drives freedom-to-operate constraints for non-originators, affecting how quickly alternative manufacturers can qualify API or develop viable generic supply.

Where IP shows up in sourcing decisions

• Any method patents on synthesis routes can constrain process changes.
• Polymorph/crystal form and impurity specifications can force replication of the original quality attributes.
• Use and formulation patents can shape what dosage forms a competitor can sell (even if API synthesis is available).

What generic or biosimilar-like “entry” risks exist for pirtobrutinib supply?

Answer: Pirtobrutinib is a small-molecule drug, so the relevant entry pathway is generic (ANDAs) and not biosimilars. Supplier diversification for generics depends on:

• API availability with compliant impurity profiles
• Patents that remain in force
• Any Paragraph IV litigation outcomes impacting approval timing

Procurement implication

Even if API is obtainable, regulatory approval timing can control which vendors become commercial suppliers in practice.

What is the Orange Book status of pirtobrutinib and how does it affect suppliers?

Answer: The Orange Book lists patents and regulatory exclusivities tied to pirtobrutinib product approvals. This governs which generic manufacturers can launch and when, which in turn governs who can become a commercial supplier post-launch.

Orange Book-driven supplier dynamics

• During exclusivity and active patent coverage, supply access for competitors is limited by licensing or litigation posture.
• Post-expiration, supplier competition typically increases across API, intermediates, and finished dose CDMOs.

What licensing or supplier agreements constrain alternative manufacturing?

Answer: Alternative manufacturing typically requires one of:

• a license from the IP holder(s)
• a non-infringing design-around with validated CMC
• a successful ANDA submission aligned to patent carve-outs

Practical effect on procurement

If licensing is not available, qualified alternative supply is delayed until patent barriers lift.

What finished dosage forms are supplied for pirtobrutinib and do they change the supplier list?

Answer: Pirtobrutinib is marketed as oral tablets. Supplier capability requirements are therefore centered on:

• small-molecule tablet formulation
• blending, compression, coating (if applicable), and tablet packaging
• dissolution and stability specifications unique to the marketed product

Why dosage form matters

A tablet CDMO lineup is not interchangeable with hard-gelatin capsule or solution manufacturing suppliers, so procurement vendor sets narrow to tablet-capable sites.

Commercial landscape: who will be the next non-originator supplier?

Answer: The next non-originator supplier pool will depend on ANDA approvals, patent litigation and settlements, and whether API supply can be qualified without infringing synthesis or formulation constraints.

What determines how fast new suppliers appear

• Patent expiration and exclusivity windows
• Whether generics file early enough for first-launch incentives
• Whether API producers are willing to invest in impurity-controlled development

Key Takeaways

• AstraZeneca anchors the US commercial pirtobrutinib finished-dose supply chain (Jaypirca).
• Open-source public records rarely identify the named API/intermediate suppliers for pirtobrutinib in a procurement-ready way.
• IP and Orange Book status strongly influence when non-originator suppliers can enter the market through ANDAs, which controls supply diversification over time.
• For vendor qualification, procurement teams typically rely on label manufacturing statements, FDA establishment registrations, and direct vendor documentation rather than public API supplier lists.

FAQs

1. How do I find pirtobrutinib tablet manufacturing sites if the label is limited?
2. What documents do API suppliers provide to qualify pirtobrutinib for GMP supply?
3. Which CMC risks matter most in pirtobrutinib API sourcing, impurity profile or polymorph control?
4. When generics launch pirtobrutinib, how quickly do new API suppliers enter commercial supply?
5. Do pirtobrutinib process patents typically block “supplier shopping” for API or only require design-arounds?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Drug Name Search: pirtobrutinib). US Food and Drug Administration.
2. FDA. Drugs@FDA: Jaypirca (pirtobrutinib) product information, regulatory history, and labeling. US Food and Drug Administration.
3. US FDA. OpenFDA OAI Establishment Registration data (site-level manufacturing listings). US Food and Drug Administration.